Publications
Page 1 of 2
September 16, 2024
Preliminary phase 1 safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors
Vincent Chung, Alex Spira, Anna Pavlick, David Sommerhalder, Brett Hall, Vinny Hayreh, Jan de Jong, Jason Funt, Sarah Kolitz, Praveen Nair, Peter King, Jenny Zhang, Jason Kim, Amy Yamamura, Benjamin…
April 9, 2024
Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models
In a poster titled, “Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models,” IMM-1-104, gemcitabine (GEM), nab-paclitaxel (PAC), and 5-fluorouracil (5-FU) were evaluated in tumor…
October 12, 2023
Deep Cyclic Inhibition of the MAPK pathway with IMM-6-415, alone and in combination with encorafenib, demonstrates anti-tumor activity and tolerability in RAF mutant tumors in vivo
Anti–tumor activity of IMM-6-415 was evaluated in more than 60 humanized 3D-TGA models, which included 30 BRAF class I-mutant tumor models. Multiple drug-drug combinations have been explored, including vertical drug…
Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors
Anti-tumor activity of IMM-1-104 was characterized in 193 tumor models spanning 20 distinct tumor types in the humanized 3D-tumor growth assay (3D-TGA) using cancer-specific, patient-aligned cell lines. IMM-1-104 demonstrated diverse…
April 18, 2023
Humanized 3D tumor models that are mutually aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors
Highlights of the initial IMM-1-104 Phase 1 PK, PD and safety data presented at AACR include (as of data cut-off date of April 10, 2023, including patients with pancreatic and…
March 7, 2023
Pan-RAS IMM-1-104 activity in humanized 3D tumor models is independent of specific amino acid substitution
Title: Pan-RAS IMM-1-104 activity in humanized 3D tumor models is independent of specific amino acid substitution Virtual poster presented at AACR Special Conference Targeting RAS March 7, 2023 Presenter: Sarah…
March 5, 2023
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid tumors harboring RAS…
November 10, 2022
Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the Dual MEK inhibitor, IMM-6-415, enhances PD-1 and CTLA-4 checkpoint blockade in RAS mutant tumors
KRAS is the most frequently altered RAS gene (~85%) and is often mutated in pancreatic ductal adenocarcinoma (PDAC; 95%), non-small cell lung cancer (NSCLC; 40%) and colorectal cancer (CRC; 45%)1….
May 26, 2022
Translational Modeling for Patients with RAS Mutant Tumors: Profiling the Dual-MEK Inhibitor IMM-1-104 in a Humanized 3D Assay
Background: Elevated RAS-RAF-MEK-ERK (MAPK pathway) signaling is observed in over half of all solid human tumors, and mutations in RAS or RAF account for a large fraction. Given MEK’s unique…
Head-to-Head Comparison of the Dual-MEK Inhibitor IMM-1-104 versus Sotorasib or Adagrasib in KRAS Mutant Pancreatic Tumors
Background: KRAS mutations are common in pancreatic ductal adenocarcinoma (PDAC). While 90% of PDAC tumors display activating mutations in KRAS, only ~2% are G12C, a specific KRAS mutation targeted by…
Page 1 of 2
